Diabetes Care, Vol 16, Issue 6 911-915, Copyright © 1993 by American Diabetes Association

ARTICLES

Comparison of bolus and infusion protocols for determining acute insulin response to intravenous glucose in normal humans. The ICARUS Group. Islet Cell Antibody Register User's Study

DK McCulloch, PJ Bingley, PG Colman, RA Jackson and EA Gale
Diabetes Clinical Research Unit, Virginia Mason Research Center, Seattle, WA 98101.

OBJECTIVE--To help standardize methodology for intravenous glucose tolerance testing in preclinical IDDM by comparing a 30-s bolus and a 3-min infusion of glucose. RESEARCH DESIGN AND METHODS--We tested 20 healthy nondiabetic adults at four centers (in Seattle, Boston, Melbourne, and London). Each subject had four intravenous glucose tolerance tests (two bolus and two infusion). The acute insulin response to glucose was calculated as the mean of the 1' + 3', the mean of 1' to 10', or as the integrated area from 0 to 10'. Glucose and insulin profiles and intrasubject coefficient of variation were compared. RESULTS--With the infusion protocol, the 1' insulin was significantly higher, resulting in a higher acute insulin response to glucose when calculated as 1' + 3' (525 +/- 66 vs. 376 +/- 35 pM, P < 0.004). When calculated over 10 min, however, the acute insulin response to glucose was not different between protocols. In addition, the intrasubject coefficient of variation was significantly better when calculated over 10 min in both protocols, but no significant differences were noted between the bolus and infusion (infusion: AIRg [area from 0 to 10'] 10.4 +/- 2.1% vs. AIRg [1' + 3'] 14.9 +/- 2.8%, P < 0.007; bolus: AIRg [area from 0 to 10'] 14.6 +/- 2.8% vs. AIRg [1' + 3'] 19.8 +/- 3.5%, P < 0.007). Comparison of the insulin assays between the four centers showed close correlation and gave indistinguishable results in terms of within-subject coefficient of variation. Glucose profiles were similar in both protocols. Although the glucose values were lower with the bolus protocol from 4' to 40', the rate of fall from 10 to 30' (and thus the rate of glucose disposal) was indistinguishable between the two. CONCLUSIONS--These data suggest that neither protocol gives significant advantage over the other. However, to allow comparison of the acute insulin response to glucose between different protocols used in centers around the world, the ICARUS 3-min infusion protocol is recommended, with acute insulin response to glucose calculated over 10 min after the end of glucose administration; this reduces the within-subject coefficient of variation and provides similar acute insulin response to glucose with both protocols.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. A. Sherry, E. B. Tsai, and K. C. Herold Natural History of {beta}-Cell Function in Type 1 Diabetes Diabetes, December 1, 2005; 54(suppl_2): S32 - S39. [Abstract] [Full Text] [PDF]

				J. P. Krischer, D. D. Cuthbertson, and C. Greenbaum Male Sex Increases the Risk of Autoimmunity but not Type 1 Diabetes Diabetes Care, August 1, 2004; 27(8): 1985 - 1990. [Abstract] [Full Text] [PDF]

				M. K. S. Leow, C. L. Addy, and C. S. Mantzoros Human Immunodeficiency Virus/Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome: Clinical Presentation, Pathophysiology, and Therapeutic Strategies J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1961 - 1976. [Full Text] [PDF]

				C. J. Greenbaum and L. C. Harrison Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes Diabetes, May 1, 2003; 52(5): 1059 - 1065. [Full Text] [PDF]

				M.-R. Pastore, E. Bazzigaluppi, C. Belloni, C. Arcovio, E. Bonifacio, and E. Bosi Six Months of Gluten-Free Diet Do Not Influence Autoantibody Titers, but Improve Insulin Secretion in Subjects at High Risk for Type 1 Diabetes J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 162 - 165. [Abstract] [Full Text] [PDF]

				C. J. Greenbaum, D. Cuthbertson, and J. P. Krischer Type 1 Diabetes Manifested Solely by 2-h Oral Glucose Tolerance Test Criteria Diabetes, February 1, 2001; 50(2): 470 - 476. [Abstract] [Full Text]

				C. J. Greenbaum, D. A. Schatz, D. Cuthbertson, A. Zeidler, G. S. Eisenbarth, and J. P. Krischer Islet Cell Antibody-Positive Relatives with Human Leukocyte Antigen DQA10102, DQB10602: Identification by the Diabetes Prevention Trial-Type 1 J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1255 - 1260. [Abstract] [Full Text]

				R. H. Slover and G. S. Eisenbarth Prevention of Type I Diabetes and Recurrent {beta}-Cell Destruction of Transplanted Islets Endocr. Rev., April 1, 1997; 18(2): 241 - 258. [Abstract] [Full Text]